Open AccessThe site of apalutamide in the treatment of prostate cancer
Author(s) -
Kajetan Juszczak,
Tomasz Drewa
Publication year - 2021
Publication title -
oncoreview
Language(s) - English
Resource type - Journals
eISSN - 2450-6125
pISSN - 2353-852X
DOI - 10.24292/01.or.124221921
Subject(s) - prostate cancer , medicine , testosterone (patch) , oncology , cancer , prostate , androgen receptor
Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. The article presents the role of apalutamide in the treatment of prostate cancer and its effectiveness. Moreover, attention was drawn to the need for close cooperation between the urologist and the oncologist in order to optimize the treatment of a patient with progressive prostate cancer.